Replies to post #122352 on Biotech Values

[DewDiligence]

BIOD/HALO—I’m modestly bearish on the various fast-acting insulin programs. I posted the following three years ago (#msg-32024599) and my view hasn’t changed much:

The various insulin analogs (what Novo-Nordisk calls “modern insulins”) are steadily gaining market share at the expense of ordinary insulin. A tweaked formulation of ordinary insulin, even if it works, is not exactly a winning business idea, IMO.

Also see the comments in #msg-32045163, although these may not be relevant anymore.